PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
- Written by PR Newswire Asia - Asian Spectator
Highlights:
- Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®
- Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R
- Confirmation that monepantel and its active metabolite, monepantel...